Harold Hoar, co-founder of trucking company Hoar Transportation Limited, left a residual bequest to the Society in his will.
Half a century ago, hardworking entrepreneur Harold Hoar chose to support one of his favourite charities by naming the Canadian Cancer Society in his will. After making sure his family would be taken care of, he left the residual of his estate to the Society.
“May is ‘Leave a Legacy Month’, a wonderful opportunity to celebrate the many donors whose generosity lives on through a bequest in their will to the Society,” says Tony Lee, Director, Leadership Philanthropy. “Whether an individual chooses to support a specific area of cancer research, or one of our information and support programs, they know that their gift will have a powerful impact.”
As it turns out, Harold’s gift to cancer research helped fund a momentous discovery in cell biology in the 1960s. Since cancer research is constantly evolving and building on previous discoveries, Harold’s bequest continues to pay dividends in the fight against cancer to this day.
A generation later, Paul Turner reflects on his stepfather’s willingness to help others. “He had a gleam in his eye whenever he was particularly pleased about something. I know he’d be very proud of the impact his gift has had in the cancer fight and the lives it has saved.”
In naming the Canadian Cancer Society in his will, Harold was able to make a gift of whatever is left in his estate once other priority bequests (for example to his children and grandchildren) have been discharged. Through careful tax planning, the gift ended up having very little effect on what his beneficiaries would have otherwise received.
For more information, please contact Tony Lee, Director, Leadership Philanthropy
Tel: 1-800-268-8874, ext. 7122
After seeing a Canadian Cancer Society call for volunteers in a newspaper, Rosemary knew that this was her opportunity to get started.
A clinical trial led by the Society’s NCIC Clinical Trials group found that men with prostate cancer who are treated with intermittent courses of hormone therapy live as long as those receiving continuous therapy.